Spineway SA (37S) AI Stock Analysis

Spineway SA

(Frankfurt:37S)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Sustained Revenue GrowthSteady revenue growth through 2025 indicates continued demand for Spineway’s spinal implants and surgical systems. Maintaining top-line expansion provides a foundation for operating improvement, supports investment in the product portfolio, and creates greater opportunity to convert sales growth into future profitability.

Negative Factors

Persistent LossesContinued net losses show that revenue growth and margin recovery have not yet produced a sustainable earnings base. Persistent unprofitability can restrict internally funded investment, weaken the ability to absorb operating setbacks, and leave the company dependent on further improvement before returns become durable.

Spineway SA (37S) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 3.09M
Dividend Yield: ―
Average Volume (3M): 3,977
Price to Earnings (P/E): -1.3
Beta (1Y): 0.55
Revenue Growth: 14.51%
EPS Growth: 59.71%
Country: Germany
Employees: 43
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Specialties

Spineway SA Business Overview & Revenue Model

Company Description

Spineway SA designs, develops, and markets a range of surgical implants for spine in France. The company offers posterior fixation, including posterior osteosynthesis systems and minimal invasive posterior osteosynthesis systems; interbody fusion pro...

Spineway SA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:37S against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FR:CVX	52Neutral	EUR 352.20M	-8.71	-120.57%	―	-100.00%	-72.33%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FR:ALIMP	45Neutral	EUR 21.40M	-5.18	671.47%	―	24.35%	15.00%

* Healthcare Sector Average

Performance Comparison

DE:37S and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:37S	Spineway SA	0.08	-0.06	-41.84%
FR:ALSAF	Safe Orthopaedics	0.64	-1.76	-73.33%
FR:CVX	Affluent Medical SA	5.66	4.07	255.97%
FR:ALIMP	Implanet SA	0.15	-0.09	-38.59%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Spineway SA AI Stock Analysis